Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Ranbaxy Wins U.S. Approval to Sell Generic of Pfizer’s Lipitor

Ranbaxy Laboratories Ltd., India’s biggest drugmaker, won U.S. clearance to sell a generic version of Pfizer Inc.’s $10.7 billion Lipitor cholesterol pill.

The Food and Drug Administration approved Ranbaxy’s copy of the world’s top-selling drug, which will be manufactured by Ohm Laboratories in New Brunswick, New Jersey, the agency said today in a statement. Watson Pharmaceuticals Inc. today began selling a copy of Lipitor in the U.S. under an agreement with New York-based Pfizer. Watson’s version didn’t require FDA clearance because Pfizer is providing the drug to sell without the brand label in return for a share of the revenue.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.